格隆汇9月25日|安进公司宣布,用于治疗罕见肌无力症的药物inebilizumab或Uplizna达到了后期研究的主要目标。重症肌无力是由异常免疫反应引起的,这种反应会削弱控制眼睛、嘴巴、喉咙和四肢的肌肉。在试验中,接受该药物治疗的患者在26周后,在常用的衡量疾病对日常活动影响的量表上显示出4.2分的改善,或经安慰剂调整后为1.9分。杰富瑞分析师Michael Yee表示,这些数据是“积极的上行...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.